Cargando…
AEBP1 as a potential immune-related prognostic biomarker in glioblastoma: a bioinformatic analyses
BACKGROUND: Adipocyte enhancer binding protein 1 (AEBP1) has been shown to be closely related to cancer progression; however research on its potential role in glioblastoma (GBM) remains limited. METHODS: Following an expression analysis of AEBP1 in GBM through the Oncomine database, other critical f...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667146/ https://www.ncbi.nlm.nih.gov/pubmed/34988166 http://dx.doi.org/10.21037/atm-21-5183 |
_version_ | 1784614341276860416 |
---|---|
author | Liu, Mingjian Yu, Yuyu Zhang, Ziqian Chen, Zhenghong Chen, Bin Cheng, Yijun Wei, Yongxu Li, Jia Shang, Hanbing |
author_facet | Liu, Mingjian Yu, Yuyu Zhang, Ziqian Chen, Zhenghong Chen, Bin Cheng, Yijun Wei, Yongxu Li, Jia Shang, Hanbing |
author_sort | Liu, Mingjian |
collection | PubMed |
description | BACKGROUND: Adipocyte enhancer binding protein 1 (AEBP1) has been shown to be closely related to cancer progression; however research on its potential role in glioblastoma (GBM) remains limited. METHODS: Following an expression analysis of AEBP1 in GBM through the Oncomine database, other critical findings were accessed via The Cancer Genome Atlas (TCGA) and Genotype Tissue Expression (GTEx) databases. Specifically, in addition to identifying differentially expressed genes, the Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) were further investigated. Additionally, a gene set enrichment analysis (GSEA) was performed to examine the enrichment pathways in the AEBP1 high-expression group. To examine the prognostic role of AEBP1 in GBM, survival information was obtained from the Chinese Glioma Genome Atlas (CGGA) database. Finally, the relationship between the expression of AEBP1 and immune infiltration in GBM was examined by using the “Gene Module”, “Survival Module”, and “SCNA Module” on the website “Tumor Immune Estimation Resource (TIMER)”. RESULTS: The Oncomine database revealed that AEBP1 was highly expressed in GBM. The prognostic analyses of 4 independent databases (i.e., TCGA, GTEx, Oncomine, and CGGA) revealed that AEBP1 was an independent predictable marker of GBM. The results of the GSEA showed that protein export, prion disease, cytokine receptor interaction, hematopoietic cell lineage, cell adhesion molecules, apoptosis, and the complement and coagulation cascades were differentially enriched in highly expressed AEBP1 phenotypes. Hence the conclusion is that the high expression of AEBP1 is closely correlated to poor prognosis of GBM. The immune analysis demonstrated that AEBP1 copy number alteration might affect immune infiltration in GBM tissues, and thus the survival outcomes of GBM patients. CONCLUSIONS: High AEBP1 expression in GBM is closely correlated to patient prognosis. AEBP1 is a potential therapeutic target for the inhibition of cancerous progression and the development of new immunotherapies for GBM. |
format | Online Article Text |
id | pubmed-8667146 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-86671462022-01-04 AEBP1 as a potential immune-related prognostic biomarker in glioblastoma: a bioinformatic analyses Liu, Mingjian Yu, Yuyu Zhang, Ziqian Chen, Zhenghong Chen, Bin Cheng, Yijun Wei, Yongxu Li, Jia Shang, Hanbing Ann Transl Med Original Article BACKGROUND: Adipocyte enhancer binding protein 1 (AEBP1) has been shown to be closely related to cancer progression; however research on its potential role in glioblastoma (GBM) remains limited. METHODS: Following an expression analysis of AEBP1 in GBM through the Oncomine database, other critical findings were accessed via The Cancer Genome Atlas (TCGA) and Genotype Tissue Expression (GTEx) databases. Specifically, in addition to identifying differentially expressed genes, the Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) were further investigated. Additionally, a gene set enrichment analysis (GSEA) was performed to examine the enrichment pathways in the AEBP1 high-expression group. To examine the prognostic role of AEBP1 in GBM, survival information was obtained from the Chinese Glioma Genome Atlas (CGGA) database. Finally, the relationship between the expression of AEBP1 and immune infiltration in GBM was examined by using the “Gene Module”, “Survival Module”, and “SCNA Module” on the website “Tumor Immune Estimation Resource (TIMER)”. RESULTS: The Oncomine database revealed that AEBP1 was highly expressed in GBM. The prognostic analyses of 4 independent databases (i.e., TCGA, GTEx, Oncomine, and CGGA) revealed that AEBP1 was an independent predictable marker of GBM. The results of the GSEA showed that protein export, prion disease, cytokine receptor interaction, hematopoietic cell lineage, cell adhesion molecules, apoptosis, and the complement and coagulation cascades were differentially enriched in highly expressed AEBP1 phenotypes. Hence the conclusion is that the high expression of AEBP1 is closely correlated to poor prognosis of GBM. The immune analysis demonstrated that AEBP1 copy number alteration might affect immune infiltration in GBM tissues, and thus the survival outcomes of GBM patients. CONCLUSIONS: High AEBP1 expression in GBM is closely correlated to patient prognosis. AEBP1 is a potential therapeutic target for the inhibition of cancerous progression and the development of new immunotherapies for GBM. AME Publishing Company 2021-11 /pmc/articles/PMC8667146/ /pubmed/34988166 http://dx.doi.org/10.21037/atm-21-5183 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Liu, Mingjian Yu, Yuyu Zhang, Ziqian Chen, Zhenghong Chen, Bin Cheng, Yijun Wei, Yongxu Li, Jia Shang, Hanbing AEBP1 as a potential immune-related prognostic biomarker in glioblastoma: a bioinformatic analyses |
title | AEBP1 as a potential immune-related prognostic biomarker in glioblastoma: a bioinformatic analyses |
title_full | AEBP1 as a potential immune-related prognostic biomarker in glioblastoma: a bioinformatic analyses |
title_fullStr | AEBP1 as a potential immune-related prognostic biomarker in glioblastoma: a bioinformatic analyses |
title_full_unstemmed | AEBP1 as a potential immune-related prognostic biomarker in glioblastoma: a bioinformatic analyses |
title_short | AEBP1 as a potential immune-related prognostic biomarker in glioblastoma: a bioinformatic analyses |
title_sort | aebp1 as a potential immune-related prognostic biomarker in glioblastoma: a bioinformatic analyses |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667146/ https://www.ncbi.nlm.nih.gov/pubmed/34988166 http://dx.doi.org/10.21037/atm-21-5183 |
work_keys_str_mv | AT liumingjian aebp1asapotentialimmunerelatedprognosticbiomarkeringlioblastomaabioinformaticanalyses AT yuyuyu aebp1asapotentialimmunerelatedprognosticbiomarkeringlioblastomaabioinformaticanalyses AT zhangziqian aebp1asapotentialimmunerelatedprognosticbiomarkeringlioblastomaabioinformaticanalyses AT chenzhenghong aebp1asapotentialimmunerelatedprognosticbiomarkeringlioblastomaabioinformaticanalyses AT chenbin aebp1asapotentialimmunerelatedprognosticbiomarkeringlioblastomaabioinformaticanalyses AT chengyijun aebp1asapotentialimmunerelatedprognosticbiomarkeringlioblastomaabioinformaticanalyses AT weiyongxu aebp1asapotentialimmunerelatedprognosticbiomarkeringlioblastomaabioinformaticanalyses AT lijia aebp1asapotentialimmunerelatedprognosticbiomarkeringlioblastomaabioinformaticanalyses AT shanghanbing aebp1asapotentialimmunerelatedprognosticbiomarkeringlioblastomaabioinformaticanalyses |